Martin Babler

Mr. Martin Babler is a Chairman, President & Chief Executive Officer at Alumis, Inc., an Independent Director at Prelude Therapeutics, Inc., an Independent Director at Omega Alpha SPAC and a Director-Emerging Companies Section at Biotechnology Innovation Organization.
He is on the Board of Directors at Prelude Therapeutics, Inc., Omega Alpha SPAC and Sardona Therapeutics, Inc. Mr. Babler was previously employed as an Independent Director by 89bio, Inc., an Independent Director by Neoleukin Therapeutics, Inc., an Independent Director by ZS Pharma, Inc., a President, Chief Executive Officer & Director by Principia Biopharma, Inc., an Independent Director by Infinity Pharmaceuticals, Inc., a President & Chief Executive Officer by Talima Therapeutics, Inc., a Vice President-Immunology Sales & Marketing by Genentech, Inc., and a Principal by Eli Lilly & Co.